Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

Graeme Greenfield, Ross McMullan, Nuala Robson, Julie McGimpsey, Mark Catherwood, Mary Frances McMullin

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
71 Downloads (Pure)

Fingerprint Dive into the research topics of 'Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia'. Together they form a unique fingerprint.

Medicine & Life Sciences